Company Encyclopedia
View More
name
Joincare
600380.SH
Joincare Pharmaceutical Group Industry Co.,Ltd. engages in the research, development, production, and sale of pharmaceuticals and health care products in China. The company offers chemical pharmaceuticals for respiratory, gastroenterology, assisted reproduction, psychiatry, and anti-infection; chemical APIs and intermediates for drugs for humans and veterinary drugs; and traditional Chinese medicine, including cold medicine anti-viral granules and anti-tumor medicine. It also provides diagnostic reagents and equipment, such as mycoplasma pneumoniae IgM antibody test and antinuclear antibody test kit; OTC products which includes Taitai and Jingxin oral liquid, Eagle’s American ginseng tea, and Yike Tie; and biologics comprising tocilizumab and mouse nerve growth factor injection.
3.157 T
600380.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking87/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE9.31%B
    • Profit Margin8.99%B
    • Gross Margin64.94%A
  • Growth ScoreD
    • Revenue YoY-4.38%D
    • Net Profit YoY-7.10%C
    • Total Assets YoY-0.44%D
    • Net Assets YoY2.28%C
  • Cash ScoreC
    • Cash Flow Margin1112.44%B
    • OCF YoY-4.38%D
  • Operating ScoreC
    • Turnover0.42C
  • Debt ScoreB
    • Gearing Ratio33.13%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Joincare Pharma's Q3 Profit Falls 9% as Revenue Slips 2%

    Joincare Pharma's Q3 Profit Falls 9% as Revenue Slips 2%

    marketscreener·
    SH
    600380
    -0.24%
    marketscreener·
    SH
    600380
    -0.24%

    Joincare: In the third quarter, the net profit attributable to the parent company was 306 million yuan, a year-on-year decrease of 8.61%

    On October 24th, Joincare announced that in the third quarter of 2025, it achieved operating revenue of 3.579 billion yuan, a year-on-year decrease of 2.31%; the net profit attributable to shareholders of the listed company was 306 million yuan, a year-on-year decrease of 8.61%; the basic earnings per share were 0.17 yuan

    Zhitong·
    SH
    600380
    -0.24%
    Zhitong·
    SH
    600380
    -0.24%

    Joincare Pharmaceutical Q3 Net Profit Down 8.6% Y/Y

    Joincare Pharmaceutical Group Industry Co Ltd :Q3 NET PROFIT DOWN 8.6% Y/Y

    Reuters·
    SH
    600380
    -0.24%
    Reuters·
    SH
    600380
    -0.24%

    Joincare: Indirectly holds equity in Moore Threads

    Joincare stated on the interactive platform that the company, through its wholly-owned subsidiary TaiTai Pharmaceutical, has invested in the Qianhai Equity Investment Fund. According to public information, the Qianhai mother fund holds a small amount of equity in Moore Threads, and the company's shareholding in Moore Threads is achieved indirectly through this multi-layered investment structure, with a very low final shareholding ratio

    Zhitong·
    SH
    600380
    -0.24%
    Zhitong·
    SH
    600380
    -0.24%

    Joincare: Net profit in the first half of the year was 785 million yuan, a year-on-year increase of 1.1%

    Joincare disclosed its 2025 semi-annual report on the evening of August 22. The company achieved operating revenue of 7.898 billion yuan in the first half of the year, a year-on-year decrease of 4.08%; net profit attributable to the parent company was 785 million yuan, a year-on-year increase of 1.1%; basic earnings per share were 0.43 yuan. During the reporting period, due to some generic products being included in centralized procurement, the market competition became more intense, leading to a certain decline in revenue in the chemical preparation sector. The health food sector still achieved a growth of 35% compared to the high base in the same period last year

    Zhitong·
    SH
    600380
    -0.24%
    Zhitong·
    SH
    600380
    -0.24%
    © 2025 Longbridge｜Disclaimer